Jingsong Mao

971 citations
45 papers · 732 indexed · h-index 17
Topics
Nanoplatforms for cancer theranostics (17 papers)Hepatocellular Carcinoma Treatment and Prognosis (13 papers)Nanoparticle-Based Drug Delivery (5 papers)
Journals
Advanced MaterialsSHILAP Revista de lepidopterologíaBiomaterials
Partner nations
ChinaSingaporeMacao

In The Last Decade

Jingsong Mao

42 papers receiving 726 citations

Peers

Jingsong Mao
Comparison fields: 5 of 92
  • Biomedical Engineering 456
  • Hepatology 145
  • Materials Chemistry 130
  • Biomaterials 126
  • Pulmonary and Respiratory Medicine 124
Replace Akinaga Sonoda with:
Akinaga Sonoda Japan
Guobin Hong China
Guofeng Zhou China
Pan He China
Jinshun Xu China
Tsai‐Yueh Luo Taiwan
David L. Woods United States
Rufang Liao China
Xinming Zhao China
Fuyuki Inagaki Japan
Jingsong Mao relative to Akinaga Sonoda Japan Akinaga Sonoda's profile →
Citations per field
00.5×6.4×
Akinaga Sonoda · 1×
Citations per year

Countries citing papers authored by Jingsong Mao

Since Specialization
Citations

This map shows the geographic impact of Jingsong Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingsong Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingsong Mao more than expected).

Fields of papers citing papers by Jingsong Mao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jingsong Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingsong Mao. The network helps show where Jingsong Mao may publish in the future.

Co-authorship network of co-authors of Jingsong Mao

This figure shows the co-authorship network connecting the top 25 collaborators of Jingsong Mao. A scholar is included among the top collaborators of Jingsong Mao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jingsong Mao. Jingsong Mao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 9
2 4
3 1
4 24
5 2
6 0
7 0
8 1
9 1
10 7
11 12
12 14
13 36
14 25
15 34
16 1
17 39
18 62
19 4
20 34

About Jingsong Mao

Jingsong Mao is a scholar working on Hepatology, Biomedical Engineering and Biomaterials, having authored 45 papers that have together received 732 indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (17 papers), Hepatocellular Carcinoma Treatment and Prognosis (13 papers) and Nanoparticle-Based Drug Delivery (5 papers). The work is most often cited by research in Hepatology (145 citations), Biomedical Engineering (456 citations) and Biomaterials (126 citations). Jingsong Mao has collaborated with scholars based in China, Singapore and Macao. Frequent co-authors include Gang Liu, Hongwei Cheng, Chengchao Chu, Yang Zhang, Hu Chen, Zhixiang Lu, Shuang Bai, Dengfeng Li, Pan He and Dazhuang Xu. Their work appears in journals such as Advanced Materials, SHILAP Revista de lepidopterología and Biomaterials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026